Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gene Therapy for X-Linked CGD
NCT00564759Phase 2Unknown
- Sponsor
- Universitätsklinikum Frankfurt
- Start
- Jan 2004
- Modality
- Gene Editing, Retroviral Vectors, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of SF71-gp91phox transduced CD34+ cells in X-linked chronic granulomatous disease (X-CGD), sponsored by Universitätsklinikum Frankfurt. Status: unknown.
02
Drugs
SF71-gp91phox transduced CD34+ cells
03
Conditions
X-linked chronic granulomatous disease (X-CGD)
Beyond the preview
Go deeper on NCT00564759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00564759.